Spots Global Cancer Trial Database for mrg002
Every month we try and update this database with for mrg002 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors | NCT04941339 | Advanced Solid ... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC) | NCT04742153 | Advanced or Met... | MRG002 | 18 Years - | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer | NCT04839510 | Locally Advance... Metastatic Urot... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). | NCT05141786 | Non-small- Cell... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer | NCT04837508 | Advanced or Met... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors | NCT04941339 | Advanced Solid ... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). | NCT05141786 | Non-small- Cell... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients | NCT05263869 | Breast Cancer W... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer | NCT05754853 | Advanced or Met... | MRG002 Docetaxel Injec... Paclitaxel Inje... Gemcitabine Hyd... Pemetrexed Diso... | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer | NCT04924699 | Advanced Breast... Metastatic Brea... | MRG002 Trastuzumab Emt... | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer | NCT04837508 | Advanced or Met... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. | NCT05338957 | Advanced Malign... | MRG002+HX008 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. | NCT05338957 | Advanced Malign... | MRG002+HX008 | 18 Years - 75 Years | Shanghai Miracogen Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
